Drug abuse (DA) and addiction is a complex brain disease characterized by compulsive drug craving, seeking, and use that persist in spite of severe adverse consequences. The basic mechanisms of DA have been explored for decades. It is well accepted that abused substances can disrupt activity of normal nerve cells by interacting with many proteins, particularly G-protein coupled receptors (GPCRs). A few medicines that target the central nervous system (CNS) can also modulate DA related proteins, such as GPCRs, which can act in conjunction with the controlled psychoactive substance(s) and increase side effects. To fully explore the molecular interaction networks that underlie DA and to effectively modulate the GPCRs in these networks with small molecules for DA treatment, we built a drug-abuse domain specific chemogenomics knowledgebase (DA-KB) to centralize the reported chemogenomics research information related to DA and CNS disorders in an effort to benefit researchers across a broad range of disciplines. We then focus on the analysis of GPCRs as many of them are closely related with DA. Their distribution in human tissues was also analyzed for the study of side effects caused by abused drugs. We further implement our computational algorithms/tools to explore DA targets, DA mechanisms and pathways involved in polydrug addiction and to explore polypharmacological effects of the GPCR ligands. Finally, the polypharmacology effects of GPCRs-targeted medicines for DA treatment were investigated and such effects can be exploited for the development of drugs with polypharmacophore for DA intervention. The chemogenomics database and the analysis tools will help us better understand the mechanism of drugs abuse and facilitate to design new medications for system pharmacotherapy of DA.

Keywords: drug abuse, GPCRs, polypharmacology, polydrug addiction, chemogenomics, cloud computation, target prediction, systems pharmacology
or transmembrane proteins in brain CNS system. For example, methadone, buprenorphine, and naltrexone are available for individuals addicted to opioids, whereas nicotine preparations and medications (varenicline and bupropion) are available for treatment of tobacco addiction. Some unintended consequences of these treatments, however, are causes for concern. For example, long-term methadone treatment can cause negative changes in the brain, according to recent studies (Andersen et al., 2012; Sankararaman et al., 2012). Methadone use accounted for more than 30 percent of overdose deaths from prescription painkillers in the US, despite accounting for only 2 percent of pain prescriptions as reported by the Center for Disease Control and Prevention (CDC, 2014). As such, there remains a great demand for design and discovery of new medications for the treatment of DA by targeting at GPCRs.

Another major challenge in the development of CNS drugs for DA treatment is the polypharmacology associated with GPCRs and other CNS targeting molecules. Polypharmacology is defined as the activity of compounds on multiple targets (Peters, 2012). Methadone, for example, can interact with at least the μ, δ, and κ opioid receptors, an important rhodopsin or class A GPCR family. Likewise, a number of medicines that target the CNS diseases can also modulate the DA-related proteins, which can act in concert with controlled psychoactive substances and increase side effects. The atypical antipsychotic drug clozapine, for example, shows antagonist activity at multiple aminergic GPCR family, such as the 5HT, dopamine, muscarinic, histamine, and adrenergic receptors, some of which are associated with efficacy and others with side effects (Morphy et al., 2004; Morphy, 2012). More examples can be found in the current literature (Kroese and Roth, 2012). Another important consideration is that DA and addiction often co-occur with other mental illnesses (Regier et al., 1990). When an individual experiences addiction to more than one drug at the same time (so called polydrug addiction), he/she carries more risk than one addicted to a single drug, due to an increase in side effects and drug synergy. Data from the DA Warning Network indicate that the majority of patients with prescriptions for benzodiazepines or opioids who are admitted to the emergency room had recently used one or more other substances, most frequently alcohol (SAMHSA, 2009). The ideal treatment should therefore break the addiction to each drug. The design of medicines for DA treatment must address the polypharmacology problem through: (i) lessening unwanted off-target activities that may lead to adverse drug reactions; and (ii) designing polypharmacological drugs with multiple activities across DA-related target classes, such as GPCRs, ion channels, or kinases for improved therapies (Peters, 2012). It is advantageous to utilize a polypharmacological approach in this manner to treat polygenic diseases, such as DA, in which a network of disease-related targets are modulated, as opposed to “switching” a single target on or off. Indeed, we have developed and implemented chemical genomics as a novel, powerful tool to address polydrug addiction networks related to these complicated concerns and challenges.

In this manuscript, we reported an integrated platform of cloud computing and cloud sourcing DA chemogenomics knowledgebase (DA-KB) for CNS system pharmacotherapy and new medicinal drug discovery (www.CBLigand.org/DAKB, or www.CBLigand.org/CloudDA). Domain-specific DA-KB database and polypharmacological target identification methods were constructed using our recently published chemogenomics based TargetHunter program (Wang et al., 2013), and GPU-accelerated machine learning/cheminformatics/bioinformatics algorithms and tools (Ma et al., 2011a,b, 2013; Myint et al., 2012). As reported, chemical genomics (or chemogenomics) is an interdisciplinary research field that utilizes chemicals/drugs and associated genomics data produced by in vitro and in silico techniques to systematically identify, analyze and/or predict chemicals-protein interactions for the purpose of enhancing new medicine design. Computational chemogenomics draws from the chemoinformatics and bioinformatics disciplines to produce useful information systems for researchers in pursuit of chemogenomics data, predictive modeling, as well as techniques in ligand- and structure-based drug design (Jacoby, 2011). It transforms the one-target-one-drug development process to a new multi-target-multi-drug paradigm; as such it is appropriate for the study of polydrug polypharmacology networks of DA chemicals and their analogs related to DA-targeted proteins. We have applied our developed chemogenomics database and machine-learning algorithms/tools above, and aimed at polypharmacology prediction for DA research and treatment through cloud computing and sourcing services. Herein, we reported our DA domain-specific chemogenomics knowledgebase (KB) by data-mining literature and public databases to archive DA chemical molecules/substances and the protein targets associated DA signaling pathways. Specifically, we analyzed DA related GPCRs and the poly-pharmacophore effects of their ligands. This information together with our established computational technologies/tools can enable us to further analyze the DA in molecular and systems pharmacology levels, and help us to understand better the DA mechanism of actions. Ultimately, the constructed computational chemogenomics knowledgebase databases and developed computational technologies/tools will help bridge the knowledge gap between chemical structures and their biological activities related to DA, and assist scientists to conduct polypharmacological target identification and design better medicines for DA intervention for translational systems pharmacotherapy and personalized medicine research.

**MATERIALS AND METHODS**

**DRUG ABUSE (DA) DOMAIN-SPECIFIC CHEMOGENOMICS KNOWLEDGEBASE (DA-KB)**

We have data-mined DA related genes, proteins and compounds as well as associated signaling pathways from literature and public databases, and then compiled them into the DA-KB database. In addition, FDA approved CNS drugs also are included in order to study drug repurposing and the possible side effects or off-target effects, as many of these therapeutic drugs can also potentially interact with the DA-related proteins.

The DA-KB contains genes, proteins, chemical compounds, and bioassays related to DA and neuropharmacology. The current version of DA-KB consists of the following records:

- DA Genes/Proteins (current: 594 records): the reported genes related to DA (e.g., GPCRS, transporters, ion channels, and...
kinases) have been data-mined from literature and public databases, e.g., Knowledgebase for Addiction Related Genes (KARG, karg.cbi.pku.edu.cn/), and NIDA Center for Genetic Studies (nidagenetics.org/Results/cand_genes.xls). These genes were then mapped onto proteins.

- DA Chemicals (current: 0.5 million records): these DA-related chemicals/substances are the known US controlled illicit drugs and/or have been reported biologically to interact with the proteins above. All of them have been archived from journal articles, patents and public repositories such as PubChem and ChEMBL (Bender, 2010; Gaulton et al., 2012), using our established data-mining protocols and controlled vocabulary/ontology. Among these compounds, 197 of US Illicit drugs are included. We also incorporate the CNS drugs reported in the DrugBank database and the PubChem library for later study of polypharmacology and drug repurposing (Ashburn and Thor, 2004; Oprea et al., 2011).

- DA Pathways (current: 594 records): The corresponding signaling pathways for DA proteins have been mapped through public databases, such as KEGG (Kanehisa and Goto, 2000; Kanehisa et al., 2012) and DrugBank (Wishart et al., 2006, 2008; Knox et al., 2011) using our established data mining analysis tools.

- DA Bioassays (current: 49,482 records): The bioassays that can be used to validate the DA target predictions/modeling have been collected from literature and public resources, such as ChEMBL and PubChem (Xie, 2010). Such information on bioassay validation is certain to enhance collaborations among the broad scientific community.

DA-KB is not a new-born database. Actually it was rooted from our established web-interfaced cannabinoid molecular information database (CBID) repository (www.CBligand.org/cbid) (Yang et al., 2012), which was constructed using MySQL/PHP and implemented with our in-house cheminformatics tools/data-mining algorithms. The current DA-KB platform is disseminated via cloud sourcing server (www.CBligand.org/CloudDA). The current online chemoinformatics tools/programs under the GPU-acceleration computing (Ma et al., 2011a) include Target/Off-Target Predictors (TargetHunter and HTDocking) (Wang et al., 2013; HTDocking, 2013) for polydrug addiction/toxicity prediction, artificial neural network (ANN)-QSAR (Myint et al., 2012) and a blood-brain-barrier (BBB) predictor (Wang and Xie, 2010). All these have been integrated to meet the needs of the broad DA research community (Figure 1).

**RESULTS AND DISCUSSION**

**GPCRs AND DRUG ABUSE**

The DA-KB database provides chemogenomics data information and integrated cheminformatics tools/programs to allow us transform data to knowledge by analyzing the DA in both molecular and system pharmacology levels. For example, it is reported that the nucleus accumbens (NAC) and the ventral tegmental area (VTA) are the primary sites where drugs of abuse act (Nestler, 2001). Commonly abused drugs interact with receptors such as GPCRs (Table 1) on the cell surface and alter the dopamine system by prolonging the action of dopamine in the NAC or by potentiating the activation of neurons in the VTA and NAC. As such, we first analyzed the GPCRs and DA based on the established DA-KB. Table 1 lists the 85 GPCRs that are reported to be closely related to DA and CNS system, including well-known cannabinoid receptors (CB1 and CB2), dopamine receptors (D1−5), histamine receptors (H1−4), opioid receptors (Mu, Delta and Kappa), and glutamate receptors (Metabotropic glutamate receptor 1−8). Either the proteins can directly interact with abused drugs or their mutations in the genes are reported to associate with DA disorders. For example, the morphine activates opioid receptors in the VTA, NAC, and cerebral cortex.
results in feelings of reward and activates the pleasure circuit by causing greater amounts of dopamine to be released within the nucleus accumbens (Nestler and Malenka, 2004). Cannabinoids stimulate CB1 receptor (which, like D2 and opioid receptors, are Gi linked) on glutamatergic and GABAergic nerve terminals in the NAc, and on NAc neurons themselves (Nestler and Malenka, 2004). In addition, the endocannabinoid contents can be altered by chronic exposure to nicotine, ethanol or cocaine (González et al., 2002).

The over-the-counter anti-emetic diphenhydramine (DPH) has been reported to be abused for non-medicinal purposes. DPH is an H1 histamine receptor antagonist, and its abuse liability was confirmed as it interacts either directly or indirectly with neurotransmitter systems, including those using acetylcholine, serotonin, norepinephrine, dopamine, opioids or adenosine (Halpert et al., 2002). These drugs will eventually activate CREB and ΔFosB in the NAc, and will cause the cellular adaptations. On the other hand, antagonism of metabotropic glutamate 1 receptors attenuates behavioral effects of cocaine and methamphetamine in squirrel monkeys (Achat-Mendes et al., 2012) and activation of CB2 receptors by CB2 agonists within dopamine terminals can inhibit dopamine release (Xi et al., 2011; Morales and Bonci, 2012), which implies the potential of designing molecules targeting these GPCRs for DA treatment (Achat-Mendes et al., 2012; Yang et al., 2012).

The distribution information of 85 drug-abuse related GPCRs in the human body were also collected from the MetaCore database. Figure 2 shows the statistical abundance of tissue distribution of these receptors. Most of these receptors are
Table 1 | List of drug-abuse related GPCRs in the DA-KB database.

| GPCR name                                      | UniProt accession | Reported compounds | Reported bioactivities | Cited references | Abused drug/medication |
|-----------------------------------------------|-------------------|-------------------|-----------------------|-----------------|------------------------|
| Adenosine A2a receptor                         | P29274            | 9253              | 311                   | 6466            | Adenosine              |
| Adenosine A2b receptor                         | P29275            | 4214              | 151                   | 3003            |                        |
| Adenosine A3 receptor                          | P33765            | 9104              | 298                   | 5550            |                        |
| Alpha-1d adrenergic receptor                   | P25100            | 3365              | 113                   | 2072            | Lisdexamfetamine*      |
| Alpha-2a adrenergic receptor                   | P08913            | 3259              | 174                   | 1831            | Benzphetamine*         |
| Alpha-2b adrenergic receptor                   | P18089            | 2622              | 86                    | 1375            | Methamphetamine*       |
| Alpha-2c adrenergic receptor                   | P18825            | 2912              | 102                   | 1503            | Methamphetamine*       |
| Angiotensin II type 2 (AT-2) receptor          | P50052            | 2255              | 54                    | 1323            |                        |
| Beta-1 adrenergic receptor                     | P08588            | 4909              | 234                   | 3025            |                        |
| Beta-2 adrenergic receptor                     | P07550            | 6515              | 208                   | 4320            |                        |
| Beta-3 adrenergic receptor                     | P13945            | 4925              | 106                   | 2454            |                        |
| Bradykinin B2 receptor                         | P30411            | 3114              | 78                    | 1655            |                        |
| Cannabinoid CB1 receptor                       | P21554            | 9380              | 272                   | 5553            | Nabilone*              |
| Cannabinoid CB2 receptor                       | P34972            | 7760              | 256                   | 4587            | Nabilone*              |
| C-C chemokine receptor type 1                 | P32246            | 1085              | 78                    | 727             |                        |
| C-C chemokine receptor type 2                 | P41597            | 4594              | 100                   | 2500            |                        |
| C-C chemokine receptor type 4                 | P51679            | 2386              | 46                    | 1300            |                        |
| C-C chemokine receptor type 5                 | P51681            | 4731              | 133                   | 2931            |                        |
| Cholecystokinin A receptor                     | P32238            | 3612              | 105                   | 2081            |                        |
| Cholecystokinin B receptor                     | P32239            | 2375              | 125                   | 1743            |                        |
| C-X-C chemokine receptor type 3               | P49682            | 1318              | 34                    | 864             |                        |
| C-X-C chemokine receptor type 4               | P61073            | 934               | 58                    | 540             |                        |
| Cysteinyl leukotriene receptor 1              | Q9Y271            | 2631              | 65                    | 1505            |                        |
| Delta opioid receptor                          | P41143            | 9268              | 442                   | 5527            | Heroin*                |
| Dopamine D1 receptor                           | P21728            | 4187              | 211                   | 2365            | (R)-Apomorphine*       |
| Dopamine D2 receptor                           | P14416            | 10996             | 590                   | 6945            | Ketamine*              |
| Dopamine D3 receptor                           | P35462            | 6497              | 356                   | 4289            | (R)-Apomorphine*       |
| Dopamine D4 receptor                           | P21917            | 5207              | 240                   | 3261            | (R)-Apomorphine*       |
| Dopamine D5 receptor                           | P21918            | 513               | 77                    | 378             |                        |
| Endothelin receptor ETA                        | P25101            | 3839              | 110                   | 2602            |                        |
| Histamine H1 receptor                          | P35367            | 4037              | 267                   | 2717            | Diphenhydramine        |
| Histamine H2 receptor                          | P25021            | 2596              | 154                   | 1585            |                        |
| Histamine H3 receptor                          | Q9Y5N1            | 5265              | 214                   | 3359            |                        |
| Histamine H4 receptor                          | Q9H3N8            | 2278              | 118                   | 1357            |                        |
| Interleukin-8 receptor A                       | P25024            | 2036              | 33                    | 1142            |                        |
| Interleukin-8 receptor B                       | P25025            | 2412              | 58                    | 1465            |                        |
| Kappa opioid receptor                          | P41145            | 9142              | 363                   | 5066            |                        |
| Melanocortin receptor 1                        | Q01726            | 1747              | 82                    | 865             |                        |
| Melanocortin receptor 2                        | Q01718            | 4                  | 1                     | 1               |                        |
| Melanocortin receptor 3                        | P41968            | 3641              | 89                    | 1864            |                        |
| Melanocortin receptor 4                        | P32245            | 7510              | 143                   | 3869            |                        |
| Melanocortin receptor 5                        | P33032            | 3238              | 72                    | 1647            |                        |
| Mu opioid receptor                             | P35372            | 9402              | 396                   | 5600            | Morphine*              |
| Muscarinic acetylcholine receptor 1            | P11229            | 6083              | 282                   | 2646            | Cocaine*               |
| Muscarinic acetylcholine receptor 2            | P08172            | 5083              | 274                   | 3236            | Cocaine*               |
| Muscarinic acetylcholine receptor 3            | P20309            | 5345              | 250                   | 3410            |                        |
| Muscarinic acetylcholine receptor 4            | P08173            | 3174              | 149                   | 1879            |                        |
| Muscarinic acetylcholine receptor 5            | P08912            | 2900              | 114                   | 1736            |                        |
| Neurokinin 1 receptor                          | P25103            | 5328              | 227                   | 3484            |                        |
| Neurokinin 2 receptor                          | P21452            | 3400              | 131                   | 2162            |                        |
| Neuropeptide FF receptor 1                     | Q9GZQ6            | 229               | 4                     | 94              |                        |

(Continued)
Table 1 | Continued

| GPCR name                                | aUniProt accession | bReported compounds | cReported bioactivities | dCited references | eAbused drug/medication |
|-------------------------------------------|--------------------|---------------------|-------------------------|-------------------|-------------------------|
| Neuropeptide Y receptor type 1            | P25929             | 3187                | 89                      | 2066              |                         |
| Neuropeptide Y receptor type 2            | P49146             | 2586                | 63                      | 1598              |                         |
| Neuropeptide Y receptor type 4            | P50391             | 88                  | 23                      | 67                |                         |
| Neuropeptide Y receptor type 5            | Q15761             | 1453                | 62                      | 1227              |                         |
| Nociceptin receptor                       | P41146             | 2797                | 87                      | 1488              |                         |
| Platelet activating factor receptor       | P25105             | 3787                | 64                      | 2380              |                         |
| Serotonin 1a (5-HT1a) receptor            | P08908             | 6461                | 452                     | 3967              | PMA*                    |
| Serotonin 1b (5-HT1b) receptor            | P28222             | 2099                | 198                     | 1497              | Bufotenin*              |
| Serotonin 1d (5-HT1d) receptor            | P28221             | 2359                | 181                     | 1456              | DOET*                   |
| Serotonin 1e (5-HT1e) receptor            | P28566             | 221                 | 65                      | 218               |                         |
| Serotonin 1f (5-HT1f) receptor            | P30939             | 199                 | 31                      | 146               |                         |
| Serotonin 2a (5-HT2a) receptor            | P28223             | 5884                | 373                     | 4034              | Psilocin*               |
| Serotonin 2b (5-HT2b) receptor            | P41595             | 3775                | 196                     | 2227              | Mescaline*              |
| Serotonin 2c (5-HT2c) receptor            | P28335             | 6102                | 313                     | 3967              | Psilocybin*             |
| Serotonin 4 (5-HT4) receptor              | Q13639             | 1192                | 78                      | 549               |                         |
| Serotonin 5a (5-HT5a) receptor            | P47898             | 675                 | 106                     | 639               |                         |
| Serotonin 6 (5-HT6) receptor              | P50406             | 5857                | 232                     | 3462              |                         |
| Serotonin 7 (5-HT7) receptor              | P34969             | 1899                | 215                     | 1448              |                         |
| Thyroid stimulating hormone receptor      | P16473             | 29856               | 2                       | 17114             |                         |
| Trace amine-associated receptor 1         | Q96RJ0             | 266                 | 6                       | 148               | Amphetamine*            |
| Vasopressin V1a receptor                  | P37288             | 3037                | 90                      | 1875              |                         |
| Calcitonin receptor                       | P30988             | 1803                | 6                       | 890               |                         |
| Glucagon-like peptide 1 receptor          | P43220             | 107911              | 24                      | 105298            |                         |
| Vasoactive intestinal polypeptide receptor| P22241             | 1768                | 14                      | 893               |                         |
| GABA-B receptor                           | Q9UB5S             | 143                 | 7                       | 77                | Amobarbital*            |
| Metabotropic glutamate receptor 1         | Q13255             | 961                 | 90                      | 754               | JNJ16259685             |
| Metabotropic glutamate receptor 2         | Q14416             | 1201                | 86                      | 747               | LY341495                |
| Metabotropic glutamate receptor 3         | Q14832             | 241                 | 37                      | 149               | LY341495                |
| Metabotropic glutamate receptor 4         | Q14833             | 1063                | 60                      | 572               | LY341496                |
| Metabotropic glutamate receptor 5         | P41594             | 2637                | 103                     | 1742              | MPEP                    |
| Metabotropic glutamate receptor 6         | Q15303             | 218                 | 26                      | 181               |                         |
| Metabotropic glutamate receptor 7         | Q14831             | 125                 | 30                      | 83                |                         |
| Metabotropic glutamate receptor 8         | O00222             | 142                 | 29                      | 114               |                         |

*US Schedule controlled substances.

aUniProt Accession is from UniProt database (http://www.uniprot.org/)

bNumber of Reported Compounds.

cNumber of Reported Bioactivities.

dNumber of Cited References.

eRepresented Abused Drug/Medication.

PMA, 4-methoxyamphetamine or para-Methoxyamphetamine; DOET, 2,5-Dimethoxy-4-ethylamphetamine; MPEP, 2-Methyl-6-phenylethynylpyridine.

expressed in the primary sites where drugs of abuse act, such as nucleus accumbens (84), core/shell of nucleus accumbens (78), and ventral tegmental area (74). Very interestingly, these receptors are also expressed in vision system, such as retina (84), lacrimal apparatus (82), retinal pigment epithelium (84) and iris (82), which may help to explain the fact that drug abusers usually have the signs of unsteady gait bloodshot or watery eyes, dilated or constricted pupils (Silfies and DeMicco, 2013). It is well known that some drugs are illegally used for weight loss. For example, Clenbuterol, a β2 agonist, has been off-label used as a weight-loss drug (Spiller et al., 2013). Actually, 83 of these 85 GPCR proteins, including β2 adrenergic receptor, can be found in brown and white adipose tissues. Illegal drugs can affect fetus or infant (Prenatal Exposure to Drugs of Abuse, 2011), as these receptors are expressed in umbilical cord (83) and lactating mammary gland (79). Moreover, these receptors can also be found in islets of langerhans (81) and pancreas (78), evidence that abused drugs can disturb the functions of pancreas. This is consistent with the fact that drug use is associated with worse glycaemic control and higher risk of diabetic ketoacidosis (Lee et al., 2005, 2008, 2009, 2012; Lee and Campbell, 2008).
POLYPHARMACOLOGY/POLYDRUG ADDICTION ANALYSIS FOR DA RELATED GPCRs AND THEIR LIGANDS

To explore the potential interactions between DA/CNS-related drugs and proteins, we have applied our established HTDocking program for polypharmacology and polydrug addiction analysis in order to facilitate research of substance use disorders (SUDs), psychiatric or co-occurring disorders (CODs) through *in silico* molecular mechanism study. High prevalence of SUDs exists among those who have other mental illnesses and are vulnerable groups of polydrug or multiple DA use. Polydrug use often carries more risk than the use of a single drug, due to an increase in side effects and drug synergy. By exploring the molecular partners (or target proteins) of abused drugs, and further investigating the associated signaling pathways, we can elucidate the possible mechanisms of drug synergy, thereby contributing to the rational design of system pharmacotherapy and personalized medicines.

As illustrated in Figure 3A, multiple targets (small colored nodes) of six abused drugs were predicted by our HTDocking program. These predicted top candidate targets (docking score > 6.0) as well as the annotated known targets from DrugBank were compiled to build an interacting network or polypharmacology map.

It is not a surprise that our plot shows both benzodiazepines and barbiturates can bind to GABA-A receptors (green nodes in Figure 3A), which may explain the synergized CNS depressants effects reported (Li and Xu, 2008). In fact, benzodiazepines are notorious for causing death when mixed with other CNS depressants such as opioids, alcohol, or barbiturates.

Among the predicted protein targets, our data show that PDE5A (yellow node, Figure 3A) is a target shared by codeine and bromazepam. It is well known that sildenafil (or Viagra), a famous PDE5A inhibitor, is used for sexual enhancement and can cause myocardial infarction (Cakmak et al., 2012). To our knowledge so far, there is no report about direct interactions between codeine and PDE5A except that some indirect evidence showed that codeine can induce sexual dysfunction (Ricardo Buenaventura et al., 2008). In addition, PPARγ (green node, Figure 3A) is the common target of three compounds: cocaine, bromazepam, and alprazolam. A drug targeting PPARγ for treatment of diabetes, e.g., rosiglitazone, is reported to have the side effect of myocardial infarction (Nissen and Wolski, 2007). Such information on polypharmacological effects will help us better evaluate the risk of polydrug use and of associated side effects, and could lead the way to discovery of new neurotherapy.

Another interesting *in silico* finding is the cross-target effects of three drugs (methadone, naltrexone, and buprenorphine). Our HTDocking study shows that besides binding to opioid receptors (OPRD and OPRM, green nodes), these three drugs are predicted to interact with carbonic anhydrase 2 (CA2, green node, Figure 3B). The finding is consistent with literature reports that drugs targeting CA2 can cause difficulty urinating (Roth et al., 1992), while difficulty urinating is one of the known adverse effects of methadone administration. As shown in Figure 3B, MOA-B (yellow node) is predicted as one of the common targets of methadone and naltrexone, while A4 (amyloid beta protein, blue node) is shared by naltrexone and buprenorphine. Considering that MOAB and A4 are also targets for management of Alzheimer’s disease (AD), these predictions could lead to repurposing these drugs for AD treatment. The experimental validation of the computations-based predictions will be performed by our collaborators.

DESIGNING POLYPHARMACOLOGY MOLECULES TARGETING GPCRs FOR DRUG ABUSE TREATMENT

In our DA-KB, we have collected data information on drugs and therapeutic agents for treatment of substance abuse disorders, as well as drugs for treatment of alcohol and tobacco use.
FIGURE 3 | Illustration of our cloud-based HTDocking server to predict potential targets (pink nodes) and cross-targets (yellow, green and blue nodes) of compounds and to explore possible mechanisms. (A) The predicted targets of six known abused/approved drugs (opioids: codeine and DB01532; benzodiazepines: bromazepam and alprazolam; barbiturates: secobarbital and pentobarbital). MAPK10, Mitogen-Activated Protein Kinase 10; CYP2A6, cytochrome P450 family 2, subfamily A, polypeptide 6; RAB6A, RAB6A, member RAS oncogene family; PBRM1, polybromo 1; PDE5A, phosphodiesterase 5A, cGMP-specific; A4, amyloid beta protein; RB1, retinoblastoma 1; MAPK14, mitogen-activated protein kinase 14; ALDR, Aldose reductase; PPARg, Peroxisome proliferator-activated receptor gamma; GABRA(1-6):Gamma-aminobutyric acid receptor subunit alpha-(1-6); MAOB, Monoamine Oxidase B; MAP2K1(5), Mitogen-Activated Protein Kinase 1(5); LCK, Tyrosine-protein kinase Lck; ESR1, Estrogen receptor; CTD52, Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2; GRB14, Growth factor receptor-bound protein 14; GLR2, AMPA-selective glutamate receptor 2; ALDOA, Fructose-bisphosphate aldolase A; CA2, Carbonic anhydrase II; OPRD, OPRM,OPRK, Delta (Mu, Kappa)-type opioid receptor; AA2AR, Adenosine receptor A2a; MDR1, Multidrug resistance protein 1; GARS, Glycine-tRNA ligase.

disorders, and their corresponding targets from data-mining literature reports and public/commercial databases. The current records consist of 163 drugs/therapeutic agents and 20 associated proteins. The computing polypharmacology network analyses of clinical trials or approved therapeutic medicines for DA treatment are illustrated in Figure 4A. The results show four out of the seven medicines, indicated by small medicine bottles target the mu-opioid receptor (OPRM, yellow), while two drugs interacting with the cannabinoid receptor 1 (CNR1, green), Nabilone and Cannabidiol, are in clinical trial for marijuana abuse (Phase II/III, NCT01347762) and opioid-related disorders (Phase II, NCT01605539), respectively. These are member of rhodopsin family GPCRs (Table 1).

We further applied our computational tools to explore the possibility of designing polypharmacological drug molecules targeting cannabinoid 1, mu-opioid and dopamine D1 for potential treatment of cocaine craving. As shown in Figure 4, our pilot study provides an interesting illustration for rational design of such polypharmacological ligands. By applying our TargetHunter program, we revealed that some cannabinoid ligands can interact with opioid receptors and dopamine receptors, which implied the possibility to design small molecules targeting cannabinoid receptor 1, dopamine receptors and mu-opioid receptor (Figure 4B). In addition, our established pharmacophore modeling (Chen et al., 2007) analysis showed that these small molecules shared common pharmacophoric features among these three receptors (Figures 4C,D). Such putative pharmacophore information will be highly useful for medicinal chemists to design and synthesize multiple-target ligands with synergetic potential for DA treatment. In addition, literature reported that dopamine ligands prevent the increases in ERK phosphorylation, which result from cocaine, amphetamine, methamphetamine, and THC administration. Thus, dopamine receptor could be a potential target for DA treatment (Lee and Messing, 2008). Moreover, our in silico prediction is also congruent with the report by Dong et al that the CB1-expressing neurons in the NAc are critical for emotional and motivational responses, and the membrane excitability of CB1-expressing fast-spiking interneurons within the NAc shell is increased after withdrawal from cocaine exposure, which may lead to increased release of GABA (Winters et al., 2012). Currently, we are carrying out medicinal chemistry synthesis to design/synthesis and biological test such multi-functional ligands with the functional pharmacophore groups that can simultaneously interact with the three GPCRs for DA treatment. The results will be reported in a separated journal.

CONCLUSION

Taking together, we reported here a DA domain-specific chemogenomics knowledgebase repository system (DA-KB or CloudDA), including the database structure and data records as well as the implemented chemoinformatics tools/programs. With the illustrated DA polypharmacology networking analysis of GPCRs and drugs/therapeutic agents, we have demonstrated that DA-KB database can provide a powerful tool to transform
FIGURE 4 | Illustration of TargetHunter webserver (www.cbligand.org/TargetHunter) for polypharmacology DA research. (A) TargetHunter mapping literature reported (abused) drugs-targets interactions. The large (yellow, green, and red) nodes represent targets. The small nodes (pink and blue) represent drugs, among which, seven, designated by medicine bottles (blue nodes), are approved/clinical trial medicine for DA treatments: (i) methadone, naltrexone, oxycodone, and buprenorphine targeting mu-opiate receptor (OPRM, large yellow nodes); (ii) Nabilone and Cannabidiol targeting cannabinoid receptor 1(CNR1 or CB1, large green nodes); and (iii) Adrogolide targeting dopamine receptor 1(DRD1, red). (B) TargetHunter prediction for possible cross-talk interactions of cannabinoid (CB) receptors (CNR1 and CNR2; green nodes), opiate receptors (OPRK, OPRD and OPRM; yellow) and dopamine receptors (DRD1, DRD2, DRD3, DRD4, and DRD5; red). Small blue and pink nodes in the center suggest potential cross-talk. (C,D) Pharmacophore models showing the shared common pharmacophoric features of the ligands of cannabinoid receptor 1(CNR1), dopamine receptor D1 (DRD1) and mu-opioid receptor (OPRM).

the data to the knowledge related to DA research. The information will help to identify the characteristics and patterns of DA at the molecular and system pharmacology levels. Exploration of interactions between chemicals and DA proteins will allow better understanding of how genes/proteins and small molecules influence the various risks and protective factors for DA. Considering the current knowledge of GPCR distribution in the brain, these data may also help improve and expand our understanding of the brain circuitry that underlies DA. The impact will be broadened by our built cloud sourcing and cloud computing web service that can be accessed worldwide (www.CBLigand.org/CloudDA) and will certainly boost the data sharing and knowledge exchange among DA researchers and healthcare providers.

The polypharmacology effects of ligands of DA related GPCRs are very complex as showed in the preliminary analyses of cross-targets of opioids, benzodiazepines and barbiturates; target predictions of the 3 approved DA treatment drugs; and TargetHunter mapping literature reported (abused) drugs-targets interactions. The state-of-the-art computational technologies together with the chemogenomics database enable us to understand the DA in...
systems pharmacology level, for example, predicting the possible interactions with all the human proteins. Our TargetHunter and pharmacophoric study further suggested the possibility of finding and optimizing lead compounds that combine multiple desirable mechanisms of action on these GPCRs in a single new chemical entity for DA intervention.

Though our analyses focus on drug-abuse related GPCRs and their ligands, we believe such studies can be generalized to other DA related protein target families. As such, the DA-KB and associated tools will assist biologists to quickly derive the mechanisms of action for active chemicals used for DA treatment. They should help quicken target identification by prioritizing targets or target families according to the strength of the established associations with structural motifs found in small-molecule probes. They will also facilitate pharmaceutical scientists to do research for drug repurposing. Our developed algorithms and tools can predict new targets of approved drugs, thus allowing discovery of novel therapies for these drugs (particularly those that target the CNS) to fulfill unmet clinical needs. If overlap exists among the DA-related signaling pathways and those that are modulated by currently approved drugs, it is likely to repurpose such drugs for DA treatment. Given this insight, our methods will also address the needs of translational research that quickly translate basic “data” discoveries into new “knowledge” for clinical pharmacotherapy and personalized medicine (Collins, 2010).

ACKNOWLEDGMENTS

We thank Prof Herb Barry for proofreading this manuscript. Authors would like to acknowledge the financial support for the laboratory at University of Pittsburgh from the NIH R01DA025612 and HL109654 (Xiang-Qun Xie) and the State Scholarship Fund sponsored by China Scholarship Council (CSC) (No. 201206380029) (Haibin Liu). Authors would also like to acknowledge the collaboration support from the National Natural Science Foundation of China (NSFC21202201) (Qin Ouyang), and from Science and Technological Program for Dongguan’s Higher Education, Science and Research, and Health Care Institutions, Guangdong Province, China (2012105102002) (Weiwei Su).

REFERENCES

Achati-Mendes, C., Platt, D. M., and Spealman, R. D. (2012). Antagonism of metabotropic glutamate 1 receptors attenuates behavioral effects of cocaine and methamphetamine in squirrel monkeys. J. Pharmacol. Exp. Ther. 343, 214–224. doi: 10.1124/jpet.112.196295

Anderssen, J. M., Klykken, C., and Merland, J. (2012). Long-term methadone treatment reduces phosphorylation of CaMKII in rat brain. J. Pharmacol. Pharmacol. 64, 843–847. doi: 10.1011/j.2012-7158.2012.01469.x

Ashburn, T. T., and Thor, K. B. (2004). Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673–683. doi: 10.1038/nrd1468

Bender, A. (2010). Databases: compound bioactivities go public. Nat. Chem. Biol. 6, 309–309. doi: 10.1038/nchembio.354

Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., et al. (2000). The Protein Data Bank. Nucleic Acids Res. 28, 235–242. doi: 10.1093/nar/28.1.235

Brummund, K. M., Goodell, J. R., LaPorte, M. G., Wang, L., and Xie, X.-Q. (2012). Synthesis and in silico screening of a library of β-carboline-containing compounds. Beilstein J. Org. Chem. 8, 1048–1058. doi: 10.3762/bjoc.8.117

Cakmak, H. A., Ikitirimur, B., Karadag, B., and Ongen, Z. (2012). An unusual adverse effect of sildenafil citrate: acute myocardial infarction in a nitrate-free patient. BMJ Case Rep. 2012. doi: 10.1136/bcr-2012-006504

CDC. (2014). Prescription Painkiller Overdoses: Methadone. Available online at: http://www.cdc.gov/features/vitalsigns/methadoneoverdoses/

Chen, J. Z., Wang, J., and Xie, X.-Q. (2007). GPCR structure-based virtual screening approach for CB2 antagonist search. J. Chem. Inf. Model. 47, 1626–1637. doi: 10.1021/ci0700814

Collins, F. S. (2010). Opportunities for research and NIH. Science 327, 36. doi: 10.1126/science.118055

Gauton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., et al. (2012). ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100–D1107. doi: 10.1093/nkdx777

González, S., Graziá Ciscio, M., Fernández-Ruiz, J., Fezza, F., Di Marzo, V., and Ramos, J. A. (2002). Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res. 954, 73–81. doi: 10.1016/S0006-8993(02)03344-9

Grani, S., Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Weis, W. I., et al. (2012). Structure of the delta-opioid receptor bound to naltrindole. Nature 485, 400–404. doi: 10.1038/nature1111

Halpert, A. G., Olnstead, M. C., and Beninger, R. J. (2002). Mechanism and abuse liability of the anti-histamine dimethyldihydrine. Neurosci. Biobehav. Rev. 26, 61–67. doi: 10.1016/S0149-7634(01)00338-0

HTDocking. (2013). HTDocking. Identifying Possible Targets for Small Molecules by High Throughput Docking Algorithm. Available online at: http://www.chibladg.org/HTDocking

Jacoby, E. (2011). Computational chemogenomics. Wiley Interdiscip. Rev. Comput. Mol. Sci. 1, 57–67. doi: 10.1002/wcms.11

Kaneshia, M., and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30. doi: 10.1093/nar/28.1.27

Kaneshia, M., Goto, S., Sato, Y., Furumichi, M., and Tanabe, M. (2012). KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 40, D109–D114. doi: 10.1093/nkdx988

Kendler, K. S., Schmitt, E., Aggen, S. H., and Prescott, C. A. (2008). Genetic and environmental influences on alcohol, caffeine, cannabis, and nicotine use from early adolescence to middle adulthood. Arch. Gen. Psychiatry 65, 674–682. doi: 10.1001/archpsyc.65.6.674

Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., et al. (2011). DrugBank 3.0: a comprehensive resource for ‘omics’ research on drugs. Nucleic Acids Res. 39, D1035–D1041. doi: 10.1093/nkdx988

Kroese, W. K., and Roth, B. L. (2012). “7. Polypharmacological drugs: “Magic Shotguns” for psychiatric diseases,” in Polypharmacology in Drug Discovery, ed. J.-U. Peters (Hoboken, NJ: John Wiley & Sons, Inc.), 133–148. doi: 10.1002/9781118098141.ch7

Lee, A. M., and Messing, R. O. (2008). Protein kinases and addiction. Ann. N.Y. Acad. Sci. 1141, 22–57. doi: 10.1196/annals.1441.022

Lee, P., and Campbell, L. V. (2008). Diabetic ketoacidosis: the usual villain or a scapegoat? A novel cause of severe metabolic acidosis in type 1 diabetes. Diabetes Care 31, e13. doi: 10.2337/dc07-2143

Lee, P., Greenfield, J. R., and Campbell, L. V. (2008). ”Mind the gap” when managing ketoacidosis in type 1 diabetes. Diabetes Care 31, e58. doi: 10.2337/dc08-0690

Lee, P., Greenfield, J. R., and Campbell, L. V. (2009). Managing young people with Type 1 diabetes in a ‘rave’ new world: metabolic complications of substance abuse in Type 1 diabetes. Diabet. Med. 26, 328–333. doi: 10.1111/j.1464-5491.2009.02678.x

Lee, P., Greenfield, J. R., Gilbert, K., and Campbell, L. V. (2012). Recreational drug use in type 1 diabetes: an invisible accomplice to poor glycaemic control? Intern. Med. J. 42, 198–202. doi: 10.1111/j.1445-1449.2011.02653.x

Lee, P., Nicoll, A. J., McDonough, M., and Colman, P. G. (2005). Substance abuse in young patients with type 1 diabetes: easily neglected in complex medical management. Intern. J. Med. 35, 359–361. doi: 10.1093/archppc/145.994.2005.00814.x

Li, C. Y., Mao, X., and Wei, L. (2008). Genes and (common) pathways underlying drug addiction. PLoS Comput. Biol. 4:e2. doi: 10.1371/journal.pcbi.0040002
Li, K., and Xu, E. (2008). The role and the mechanism of gamma-aminobutyric acid during central nervous system development. *Neurosci. Bull.* 24, 195–200. doi: 10.1007/s12264-008-0109-3

Ma, C., Wang, L., and Xie, X.-Q. (2011a). GPU accelerated chemical similarity calculation for compound library comparison. *J. Chem. Inf. Model.* 51, 1521–1527. doi: 10.1021/ci1004948

Ma, C., Wang, L., and Xie, X.-Q. (2011b). Ligand classifier of adaptively boosting ensemble decision stumps (LiCABEDS) and its application on modeling ligand functionality for SHT-subtype GPCR families. *J. Chem. Inf. Model.* 51, 521–531. doi: 10.1021/ci100399j

Ma, C., Wang, L., Yang, P., Tong, Q., Myint, K. Z., and Xie, X.-Q. (2013). LiCABEDS II. Modeling of ligand selectivity for G-protein coupled cannabinoid receptors. *J. Chem. Inf. Model.* 53, 11–26. doi: 10.1021/ci3005914

Manglik, A., Kruse, A. C., Kobilka, T. S., Thian, F. S., Mathiesen, J. M., Sunahara, R. K., et al. (2012). Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. *Nature* 485, 321–326. doi: 10.1038/nature10954

Martin, Y. C., Korfon, J. L., and Traiphaphong, L. M. (2002). Do structurally similar molecules have similar biological activity? *J. Med. Chem.* 45, 4350–4358. doi: 10.1021/jm020155c

Moraes, M., and Bonci, A. (2012). Getting to the core of addiction: hooking CB2 ligands for drug abuse into drug abuse? *Nat. Med.* 18, 504–505. doi: 10.1038/nm.2722

Morphy, R. (2012). “12. Selective multitargeted drugs,” in *Polypharmacology in Drug Discovery*, ed J.-U. Peters (Hoboken, NJ: John Wiley & Sons, Inc.), pp. 247–262. doi: 10.1002/9781180981411.ch12

Morphy, R., Kay, C., and Rankovic, Z. (2004). From magic bullets to designed multiple ligands. *Drug Discov. Today* 9, 641–651. doi: 10.1016/S1359-6446(04)03163-0

Myint, K.-Z., Wang, L., Tong, Q., and Xie, X.-Q. (2012). Molecular fingerprint-based artificial neural networks QSAR for ligand biological activity predictions. *Mol. Pharm.* 9, 2922–2923. doi: 10.1021/mp300237f

Nestler, E. J. (2001). Molecular basis of long-term plasticity underlying addiction. *Neurosci. Lett.* 28, 119–128. doi: 10.1016/S0304-3959(01)02187-6

Nestler, E. J., and Malenka, R. C. (2004). The addicted brain. *Sci. Am.* 290, 78–85. doi: 10.1038/scientificamerican0304-78

Pozzan, A. (2006). Molecular descriptors and methods for ligand based virtual high throughput screening in drug discovery. *Curr. Pharm. Des.* 12, 2099–2110. doi: 10.2174/13816120677585247

Prental Exposure to Drugs of Abuse. (2011). NIDA Topics in Brief. Available online at: http://www.drugabuse.gov/publications/topics-in-brief/prental-exposure-to-drugs-abuse

Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Judd, S. H., et al. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. *JAMA* 264, 2511–2518. doi: 10.1001/jama.1990.0343010043026

Ricardo Buenaventura, M., Rajive Adlaka, M., and Nalini Sehgal, M. (2008). Opioid peptides have similar biological activity? a reevaluation. *Sci. Am.* 290, 78–85. doi: 10.1038/scientificamerican0304-78

Sankararaman, A., Masuili, L., Richardson, D. R., Andersen, J. M., Morland, J., and Esch, A. J. (2012). Methadone does not alter key parameters of adult hippocampal neurogenesis in the heroin-naive rat. *Neurosci. Lett.* 516, 99–104. doi: 10.1016/j.neulet.2012.03.086

Silies, P. J., and DeMico, F. J. (2013). Impact of substance abuse: human resource strategies for the hospitality industry. *Hospital. Rev.* 10:9.

Spiller, H. A., James, K. J., Scholzen, S., and Borys, D. J. (2013). A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding. *Subst. Abus.* 34, 306–312. doi: 10.1080/08897077.2013.772083

Tandon, M., Wang, L., Xu, Q., Xie, X., Wipf, P., and Wang, Q. J. (2012). A targeted library screen reveals a new inhibitor scaffold for protein kinase D. *PLoS ONE* 7:e44653. doi: 10.1371/journal.pone.0044653

Thompson, A. A., Liu, W., Chun, E., Katrich, V., Wu, H., Vardy, E., et al. (2012). Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. *Nature* 485, 395–399. doi: 10.1038/nature11085

Wang, L., Ma, C., Wipf, P., Liu, H., Su, W., and Xie, X.-Q. (2013). TargetHunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database. *AAPS J.* 15, 395–406. doi: 10.1208/s12248-014-9449-9

Wang, L., and Xie, X.-Q. (2010). An Online Blood-brain Barrier Predictor (fBBB) Based on Molecular Fingerprints. Available online at: http://www.cbligand.org/fBBB/

Wilds, B. D., Kruger, J. M., Huang, X., Gallagher, Z. R., Ishikawa, M., Craia, K., et al. (2012). Cannabinoid receptor 1-expressing neurons in the nucleus accumbens. *Proc. Natl. Acad. Sci. U.S.A.* 109, E2717–E2725. doi: 10.1073/pnas.1206303109

Xie, X.-Q. (2010). Exploiting PubChem for virtual screening. *Expert Opin. Drug Discov.* 5, 1205–1220. doi: 10.1517/17460441.2010.524924

Xie, X.-Q., Chen, J. Z. (2008). Data mining a small molecule drug screening representative subset from NIH PubChem. *J. Chem. Inf. Model.* 48, 465–475. doi: 10.1021/ci700193u

Xie, X.-Q., and Chen, J. Z. (2008). (2012). Crystal structure of the micro-opioid receptor bound to a morphinan antagonist. *Nature* 485, 321–326. doi: 10.1038/nature10939

Xi, Z. X., Peng, X.-Q., Li, X., Song, R., Zhang, H. Y., Liu, Q. R., et al. (2011). Brain cannabinoid CB(2) receptors modulate cocaine’s actions in mice. *Neurosci. Bull.* 14, 1160–1166. doi: 10.1080/08897077.2011.000003

Xie, X.-Q., and Chen, J. Z. (2008). Data mining a small molecule drug screening representative subset from NIH PubChem. *J. Chem. Inf. Model.* 48, 465–475. doi: 10.1021/ci700193u

Xie, X.-Q. (2010). Exploiting PubChem for virtual screening. *Expert Opin. Drug Discov.* 5, 1205–1220. doi: 10.1517/17460441.2010.524924

Yang, P., Wang, L., and Xie, X.-Q. (2012). Latest advances in novel cannabinoid CB2 ligands for drug abuse and their therapeutic potential. *Future Med. Chem.* 4, 187–204. doi: 10.4155/fmc.11.179

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.